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ABSTRACT
Periodontal diseases are characterized by high prevalence in many populations and 
the chronic and progressive course of the disease. A fundamental stage of treatment 
is mechanical debridement of the tooth surface. During debridement antimicrobial 
agents may be applied as adjunctive intrasulcular irrigants.
There is lack of consensus as to the optimal type of antimicrobial therapy in 
treatment of periodontal disease. A new antiseptic solution, containing polyhexa-
methylene guanidine phosphate (PHMG-P) as the active ingredient, has recently 
been marketed as an adjunctive irrigant in periodontal treatment. Since there is no 
sufficient history of oral application of this antiseptic, few scientific is evidence 
available to support its efficiency. 
The aim of the thesis was to investigate the effects of antiseptics on bacteria and 
human cells and to evaluate the efficacy of adjunctive (PHMG-P) irrigation of 
periodontal pockets during scaling and root planing (SRP). 
Clinical, microbiological and immunological parameters were evaluated. 
In the initial in vitro study (Paper I), the anti-microbial activity of antiseptics 
was investigated. Using a quantitative suspension method, PHMG-P was com-
pared with chlorhexidine (CHX) on standard quality control bacterial strains of 
Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Candida 
albicans, the periopathogens Porphyromonas gingivalis, Aggregatibacter actino-
mycetemcomitans and also Streptococcus mutans, and Lactobacillus acidophilus, 
microorganisms implicated in dental caries. In Paper II the cytotoxic and immune-
modulatory effects of the antiseptics on human gingival fibroblasts were determined. 
In Paper III the clinical efficacy of intrasulcular irrigation with PHMG-P and CHX 
as adjunctives to periodontal debridement in patients with severe chronic peri-
odontitis was investigated. Finally, Paper IV evaluated the impact of the antiseptics 
on microflora and cytokine profiles in periodontal pockets undergoing treatment. 
Papers I and II showed that PHMG-P had anti-microbial activity and cytotoxic-
ity and expressed anti-inflammatory properties. In Paper III it was shown that 
adjunctive PHMG-P irrigation improved the short-term outcome of SRP, but had 
no significant long-term effect on the mean pocket depth. Paper IV showed that 
although antiseptic treatment caused changes in biomarkers and bacterial counts, 
no differences in these parameters were observed between the treatment groups 
at any of the follow-up examinations.
Conclusion: In the in vitro studies, PHMG-P showed pronounced antimicrobial 
activity. The primary response to periodontal treatment was attributable to the 
mechanical debridement. The adjunctive antiseptic irrigants, applied in accord-
ance with the study protocol, had only limited effects.
Key words: Periodontal disease; periodontitis; periodontal treatment; antiseptics; 
chlorhexidine; polyhexamethylene guanidine phosphate; fibroblasts; cytokines; 
prostaglandin E2; matrix metalloproteinase; inflammation; periopathogens.
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11 INTRODUCTION
1.1 Periodontal diseases
The periodontium comprises the tissues supporting the tooth: the gingiva, the peri-
odontal ligament, the alveolar bone and the root cementum. Of all the periodontal 
pathologies, the most widespread are inflammatory conditions, such as gingivitis 
and periodontitis (1). While gingivitis is confined to the gingiva, periodontitis 
involves all the periodontal tissues. The main feature of periodontitis is breakdown 
of the junctional epithelium. However, it is not always easy to distinguish clini-
cally between gingivitis and slight periodontitis, i.e. to establish the fact whether 
the dentogingival junction is breached.
1.1.1 Periodontitis 
Periodontitis is defined as inflammation of the periodontal tissues, caused by 
interaction of the oral biofilm with the host immune system and manifested as 
disruption of the dento-gingival junction. If untreated, the condition progresses 
to tooth loss. Periodontitis also affects general health by increasing the risk of 
myocardial infarction and has a negative effect on quality of life (2-4). In some 
populations periodontal diseases are a grave public health challenge (5). In the 
classification by Armitage in 1999, chronic periodontitis was denoted as general-
ized or localized (6). Severity was further denoted as slight, moderate or severe. 
Recently a new system has been proposed, classifying periodontitis in terms of 
stages and grades, adding new headings for peri-implant conditions and gingival 
health on intact and reduced periodontium (1). 
1.1.2 Dental plaque
The early nonspecific plaque hypothesis postulated that periodontal inflammation 
was induced in response to plaque accumulation (7). Later the specific plaque 
concept presumed implication of certain microorganisms as causative agents of 
the disease (8). The evidence supporting this concept included the elevated levels 
of putative periopathogens in periodontal lesions, the resolution of inflammation 
after elimination of these microbes and induction of the disease in gnotobiotic rats 
by introduction of specific bacterial species (9, 10). The role of Aggregatibacter 
actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia 
was generally accepted and they were regarded as “consensus” periodontopatho-
gens. Eubacterium nodatum, Fusobacterium nucleatum, Prevotella intermedia, 
Prevotella nigrescens and Treponema denticola are also strongly associated with 
chronic periodontitis (11). More recently the biofilm has been recognized as a 
significant risk factor for periodontal diseases. The “ecological plaque hypothesis” 
was advanced (12). It formulated that the imbalance in non-pathogenic biofilm 
2auto-regulation, behavioral aspects and the host immune response maximizes the 
deleterious impact of dental plaque leading to accumulation of periopathogens 
and enhances the risk of periodontal disease. 
The biofilm incorporates single cells and microcolonies in a highly hydrated 
exopolymer matrix (13). These entrapped cells behave differently from their 
free-floating	counterparts.	A	general	characteristic	of	bioﬁlm	communities	is	that	
compared with their planktonic counterparts, they tend to be considerably more 
resistant to antibiotics and antimicrobial substances, including those generated by 
the host defense mechanisms (14, 15). The pathogenic effects of the dental biofilm 
can be moderated by alleviating the microbial burden and effectively maintaining 
normal oral biocenosis via routine hygiene and treatment procedures (16, 17).
1.1.3 Immune response 
Periodontitis is initiated by microbial plaque, but progression of the disease is 
closely associated with the host immune response (18). Host inflammatory medi-
ators play important roles in the control of periodontal infection, yet they are also 
implicated in tissue destruction (19, 20). Cytokines are soluble low molecular 
weight proteins able to bind to specific receptors, initiate intra-cellular signaling 
cascades and regulate the range and duration of the inflammatory response (21, 
22). They are produced by epithelial cells, fibroblasts and phagocytes (neutrophils 
and macrophages) in the acute phase of inflammation, and by immune cells (lym-
phocytes) in the adaptive immune response (23). 
The innate host immune system initially recognizes microbial components via 
pattern recognition receptors such as toll-like receptors (TLR)-2, TLR-4 and nucle-
otide-binding oligomerization domain receptors (24). The binding of microbial 
components to these receptors, through a series of intracellular biochemical sig-
nals, results in production of pro-inflammatory cytokines and chemokines, includ-
ing	tumor	necrosis	factor	(TNF)-α	and	interleukin	(IL)-1β,	which	in	turn	recruit	
leukocytes to the periodontal space to combat the infection (19). Subsequently 
leukocytes generate substantial amounts of inflammatory cytokines such as TNF-
α,	IL-1β	and	IL-6.	Production	of	receptor	activator	of	nuclear	factor-kB	ligand	
(RANKL) disrupts the balance in the level of osteoclast differentiation factor, 
causing osteoclastogenesis, ultimately resulting in increased resorption of alveolar 
bone (25). In addition to direct promotion of bone resorption, innate immunity 
cytokines also inhibit osteogenic differentiation (26). The local chronic inflamma-
tory reaction causes a pronounced change in the ratio of matrix metalloproteinases 
(MMP) to tissue inhibitors of metalloproteinases (TIMP) and this is responsible 
for decompensation of extracellular matrix of the connective tissues. Activated by 
antigen-presenting cells, the adaptive immune system (T and B cells) also contrib-
3utes to tissue resorption. For example, the ability of Th17 cells to produce IL-6 
and	to	up-regulate	IL-1β	and	TNF-α	synthesis	may	increase	expression	of	MMP	
and RANKL (27). Studies have also demonstrated that B-cells produce RANKL 
in response to stimulation by periodontal pathogens (28). 
In contrast to the destructive pathway involving primarily pro-inflammatory cyto-
kines, regulatory pathways mediated by the anti-inflammatory cytokines IL-10, 
IL-4 can control or attenuate disease progression (29, 30). On the one hand, pro-in-
flammatory cytokines play an essential role in clearing infection. On the other 
hand, they play destructive roles in the periodontal environment. 
Prostaglandins comprise a group of potent inflammatory mediators derived from 
arachidonic acid and induce a wide variety of biological responses (31). They 
influence vasodilatation, vascular permeability, oedema, pain and fever, and also 
play some part in neutrophil and monocyte chemotaxis (32). Prostaglandin (PG) 
E2 is one of the most prominent agents in the pathogenesis of periodontitis (33). It 
stimulates production of inflammatory mediators and MMP, as well as osteoclast 
formation via RANKL. 
Antiseptics may reduce the bacterial burden by antimicrobial action, which in turn 
suppresses inflammation by reducing the amount of pro-inflammatory cytokines 
to the level at which they no longer contribute to progression of the disease. 
In the context of current theories on the aetiology of periodontal disease, a useful 
adjunct to treatment would be an anti-inflammatory antiseptic, combining both 
bactericidal activity against periopathogens and the capacity to arrest periodontal 
tissue disintegration.
1.2 Association between periodontal diseases and 
systemic diseases
Many investigators have reported associations between periodontal and systemic 
diseases (34, 35). However, the underlying mechanisms remain unclear. There 
are two well-defined interaction mechanisms. Firstly, patients with periodontitis 
may experience more frequent and severe bacteremia, which in turn leads to expo-
sure of internal organs to oral bacteria or their by-products. Once bacteria reach 
the target organ, they can elicit an inflammatory response. The second putative 
mechanism involves cytokines generated by inflamed periodontal tissues. These 
cytokines enter the circulatory system and are transported to other organs where 
they induce an inflammatory response.
4A relationship between periodontitis and cardiovascular diseases has been estab-
lished (35). Trials showed strong evidence that periodontal treatment mitigated 
the risk of cardiovascular diseases (36). A close association was also established 
between diabetes and periodontitis, but longitudinal clinical studies, animal models 
and cell/tissue in vitro experiments are required to ascertain bidirectional mecha-
nisms interrelating both pathologies (37). 
Chronic periodontitis may also be correlated with other diseases. Several reports 
link periodontitis and chronic obstructive pulmonary disease, pneumonia, chronic 
kidney disease, rheumatoid arthritis, cognitive impairment, obesity, metabolic 
syndrome and cancer (38). Cohort studies indicate that periodontal disease is 
associated with an increased risk of premature death (39).
1.3 Periodontal treatment 
The aim of periodontitis management is to arrest inflammation, prevent contami-
nation of underlying tissues, and create conditions for healing and regeneration 
of periodontium.
The treatment generally divided into several phases: emergency, nonsurgical, sur-
gical, restorative and maintenance, which are not strictly successive. Maintenance 
care, for instance, is usually an intermission in between nonsurgical, surgical and 
restorative phases and it is routinely repeated during lifetime after successful 
treatment. Surgical or restorative phase could be omitted, if redundant. Traditional 
mechanical methods involving scaling and root planing (SRP) are non-specific 
in nature and envisage scrupulous debridement. SRP could be performed either 
gradually quadrant by quadrant with one-two week intervals or on a full-scale 
within 24 h. The chance that untreated pockets may be a source of recolonization 
for the treated sites substantiated the need of full mouth debridement (40). Better 
clinical and microbiological outcomes of periodontal treatment using full mouth 
disinfection have been reported (41). However, other research groups showing 
similar efficiency of both approaches, failed to confirm the superiority of full-mouth 
disinfection (42, 43). Gingival curettage, i.e. removal of pocket lining adjunctional 
epithelium was designed to promote attachment of new connective tissue to the 
tooth, provides no additional benefit when compared to SRP. American Dental 
Association did not recommend gingival curettage as a method of treatment and 
regarded it as a procedure of no clinical value (44).
Rough tooth surface is known to promote plaque formation (45, 46). In this regard 
should the SRP include intentional removal of root cementum? Dental calculus 
disposal implies elimination of root cementum. In the same time excessive cement 
removal is not obligatory to get rid of endotoxins and hence should be avoided (47). 
5Mechanical debridement is laborious and time-consuming and might be ineffective 
for eliminating pathogenic bacteria from periodontal pockets (48). Since microbial 
plaque is strongly implicated in periodontitis, an indispensable step in the treat-
ment protocol is to reduce the burden of periopathogens. Even after meticulous 
eradication of dental plaque some subgingival microorganisms persist (49). It is 
difficult to reach the base of pockets with curettes and the rough surface of the 
root may hinder complete removal of subgingival plaque. Studies have shown 
that failure of chronic lesions to heal may be due to insufficient eradication of 
pathogens (50). After SRP, anti-infective drugs may help reduce the number of 
periopathogenic and other microbial species in the biofilm. 
1.3.1 Antibiotics
Systemic antibiotics may be administered during treatment of chronic periodon-
titis, to promote tissue healing following SRP (51). Systemic administration of 
metronidazole and amoxicillin improves clinical outcome of non-surgical peri-
odontal treatment and reduces further surgical treatment needs (52). However, the 
undesirable side effects, including hypersensitivity, gastrointestinal disturbances 
and especially the development of bacterial resistance should be taken into account 
and antibiotics should be prescribed restrictively (53). To enhance the efficacy 
of periodontal treatment and to circumvent the undesirable effects of systemic 
antibiotics, locally delivered antimicrobials have been proposed for anti-infective 
management of periodontal diseases to modify biofilm composition and to re-
establish its autoregulation.
1.3.2 Antiseptics 
Antiseptics constitute a diverse class of antimicrobial drugs applied to skin or 
mucous membranes to treat or prevent infection. Their administration includes, but 
is not restricted to preconditioning of the skin surface prior to intervention, treat-
ment of wounds and routine disinfection of the mouth as part of an oral hygiene 
program. Intraorally, anti-infective drugs may be delivered by rinsing, by irriga-
tion, by subgingival irrigation with syringes, or by power devices. Biocides show 
a broader spectrum of activity than antibiotics and prefer specific intracellular 
targets whereas antiseptics may have multiple targets (54).
1.3.3 Mouthrinses
The first mention of mouthrinses in Chinese medical practice dates back to around 
2700 B.C. (55, 56). Even without reliable scientific evidence, our ancestors resorted 
to cleaning their teeth (57). Many oral hygiene aids, like chewing sticks, tooth 
powder and home-made mouthrinses were used. 
6In 1879 Joseph Lawrence and Jordan Wheat Lambert created a mouthwash and 
named it Listerine® to commemorate Joseph Lister, known as the father of asep-
tic surgery (58).
Nowadays various mouthwashes are available. Active ingredients include alco-
hol, fluoride, antibacterial enzymes, essential oils, cetylpyridinium chloride and 
hydrogen peroxide. However, a mouthwash cannot substitute regular oral hygiene 
self-care, such as tooth brushing and flossing. It is doubtful whether a healthy per-
son needs anti-bacterial mouthwashes to complement daily oral hygiene routine.
1.3.4 Biguanides 
The first chlorhexidine (CHX) preparation was synthetized and marketed in the 
United Kingdom in early fifties. It exhibits a potent antibacterial action against a 
wide range of both Gram-positive and Gram-negative bacteria (59). Twenty years 
later CHX found wide use in dentistry, gynecology, urology, ophthalmology and 
to date it is regarded as the gold standard among antiseptics (60, 61).
Antimicrobial action of CHX is based on its ability to alter the integrity of the 
bacterial inner membrane, leading to increased permeability and leakage of intra-
cellular ions (62). Some adverse effects of CHX include staining of the teeth and 
tongue, distorted taste sensation and desquamation of the oral mucosa (63). Aside 
from its antibacterial properties, CHX is toxic to many mammalian tissues and 
cells: sperm, macrophages, skin epithelium etc. Studies have shown that chlor-
hexidine induces a dose-dependent inhibition of cellular proliferation and reduces 
the ability of fibroblasts to produce collagen and non-collagen proteins (63). A 
more cautious approach to its use in oral surgery was advised because of possible 
adverse effects on periodontal tissue (63, 64).
Contradictory research results were obtained following application of antiseptics 
in periodontal treatment. Most studies confirm that CHX solution as an adjuvant 
to SRP does not provide additional benefit in terms of improving the clinical 
outcome of periodontal treatment (48, 65). However, M. Guarnelli et al. 2008 
demonstrated beneficial effect of CHX in ultrasonic instrumentation of patients 
suffering from aggressive periodontitis (66). Bacteremic episodes, often induced 
by SRP, are frequently associated with chronic periodontitis. Under these circum-
stances, antiseptics may decrease the release of bacteria into the blood stream (67). 
Subgingival instrumentation with concomitant povidone-iodine rinsing has been 
shown to mitigate the risk of development of oral bacteremia (68). 
7Polyhexamethylene guanidine (PHMG) derivatives are members of the polymeric 
guanidine family, widely used for many years as antiseptics in medicine and the 
food industry (69). PHMB interacts with acidic, negatively charged phospholipids 
in the bacterial membrane, causing increased fluidity, permeability and loss of 
integrity, followed by the death of the cell (70, 71). It was also found that PHMB 
could bind to nucleic acids (72). Structurally similar conjugates such as polyhexam-
ethylene biguanide hydrochloride (PHMB-H) and polyhexamethylene guanidine 
phosphate (PHMG-P) are synthesized by incorporating different anions into the 
PHMG molecule. PHMB-H has been extensively tested in vivo and in vitro. In 
the form of a mouthwash, PHMB-H consistently inhibited plaque regrowth and 
reduced oral bacterial counts, indicating its potential role as an active ingredient 
in dentifrices (73-75). 
Polyhexamethylene guanidine phosphate (PHMG-P) has been recently introduced 
for control of infections in dentistry. So far only limited data are available with 
respect to its antibacterial activity against periopathogens and its clinical efficacy 
in the treatment of periodontitis. 
82 AIMS OF THE THESIS 
2.1 Overall objective
The overall aim of the thesis was to investigate the antimicrobial, anti-inflammatory 
and cytotoxic properties of PHMG-P in preclinical studies and then to evaluate 
its efficacy under clinical conditions as an irrigant in the hygiene phase of peri-
odontal treatment.
2.2 Specific goals 
2.2.1 To define anti-microbial activity of PHMG-P against periopatho-
genic, cariogenic and standard quality control microorganisms 
compared to CHX, using the quantitative suspension method 
(Paper I).
2.2.2 To investigate the cytotoxicity of PHMG-P compared to CHX, 
and their potential modulatory effects on secretion of inflam-
matory mediators and matrix metalloproteinase (MMP) -1 by 
human gingival fibroblasts (Paper II).
2.2.3 To evaluate the clinical effects of intrasulcular irrigation with 
PHMG-P and CHX as adjunctives to periodontal debridement in 
patients with severe chronic periodontitis (Paper III).
2.2.4 To study the microflora and cytokine profiles of periodontal 
pockets following SRP with adjunctive antiseptic irrigation by 
PHMG-P or CHX (Paper IV).
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3.1 Ethical considerations
The study on human gingival fibroblasts, including the collection of gingival biop-
sies (Paper II), was approved by the Ethics Committee of Huddinge University 
Hospital, (#377/98).
The clinical trial (Paper III) was conducted according to the principles outlined 
in the Declaration of Helsinki on experimentation involving human subjects and 
approved by the Ethical Board resolution of Belarusian State Medical University 
N.5 of 18.04.2011. Every patient received written and oral information about the 
study, the substances to be used, and treatment methods. The participants also 
received a contact telephone number, in case of additional requests or any queries. 
Informed consent was obtained from every subject. Participation was voluntary 
and the subjects were free to withdraw from the study at any time. All personal 
data were coded and the keys were kept separately from the codes.
As a part of the treatment routine, all patients were informed about the results of 
examinations and diagnoses. They received no payment for their participation.
3.2 Antiseptics 
The working concentrations of antiseptics applied in clinical settings correspond 
to those dispensed in the original commodity package. The 1% PHMG-P prepa-
ration is marketed commercially as Aquin. A range of CHX concentrations from 
0.005 to 2% is available for chairside administration. In our clinical study we used 
0.2% CHX solution. Thus the working concentrations of the antiseptics were 1% 
PHMG-P and 0.2% CHX.
In Papers I and II, antiseptic solutions were prepared ex tempore in dH2O: PHMG-P 
from 70% gel, with an average molecular weight of 4000-9000 (Institute of Eco-
Technological Problems, Moscow, Russia) and CHX from 1% CHX (Apotek 
Produktion & Laboratorier AB, Stockholm, Sweden).
In Papers III and IV the commercial antiseptic Aquin (Inkraslav©, Minsk, Belarus), 
containing 1% (w/v) PHMG-P as the active substance, and 0.2% (w/v) chlorhex-
idine (Public Pharmaceutical Service, Minsk, Belarus) were used as adjunctive 
irrigants for SRP. 
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3.3 Laboratory Methods 
3.3.1 Bacterial strains and culture
The anti-bacterial activity of the antiseptics was tested against the following 
strains: Staphylococcus aureus (ATCC 6538), Escherichia coli (АТСС	11229),	
Pseudomonas aeruginosa (АТСС	15412),	Candida albicans (ATCC 1023), 
Porphyromonas gingivalis (ATCC 33277), Aggregatibacter actinomycetemcomi-
tans (HK 1519), Streptococcus mutans (CCUG 27624; Ing-Brit) and Lactobacillus 
acidophilus (NCTC 1723). The strains of S. aureus, Е. coli, P. aeruginosa and С. 
albicans were inoculated on trypticase soy agar (TSA) (Becton Dickinson, NJ, 
USA)	and	incubated	for	18-24	hours	at	37˚C.	The	number	of	these	microorganisms	
suspended in sterile PBS was adjusted by optical density (OD) and determined 
precisely by the drop count method. P. gingivalis was cultured on Colombia base 
agar (Acumedia, Baltimore, MD, USA) supplemented with hemin (0.05 mg/ml) 
(Sigma-Aldrich, Sweden AB), vitamin K (0.01 mg/ml) (BBLTM, Becton Dickinson), 
and citrated horse blood (5%) (Sigma-Aldrich), in an anaerobic atmosphere 
(GasPak, Becton Dickinson) for 7 days. The test suspension of P. gingivalis with 
OD 0.73-0.75 was prepared in Peptone Yeast Glucose broth (Becton Dickinson). 
A two day culture of A. actinomycetemcomitans, grown on Colombia base agar 
supplemented with 0.01% tryptophan and 5% citrated horse blood was suspended 
in Haemophilus Teat Medium (HTM) broth (BactoTM, Becton Dickinson). The OD 
of the suspension was adjusted to 0.76- 0.78. S. mutans was cultured on Brain 
Heart Infusion (BHI) (Oxoid, Malmö, Sweden) agar for two days and the suspen-
sion, with an OD of 0.14 was prepared in BHI broth. L. acidophilus was grown 
on Lactobacilli MRS (de Man, Rogosa and Sharpe) medium (DifcoTM, Becton 
Dickinson) for two days and the test suspension with an OD of 0.14 - 0.15 was 
prepared in Lactobacilli MRS broth. The reference strains of S. mutans, A. acti-
nomycetemcomitans, L. acidophilus were cultured in a capnophilic atmosphere 
containing 5% CO2. The turbidity of all suspensions was standardized for each bac-
terial strain spectrophotometrically at 580 nm (Biochrom WPA CO7500 Colorwave 
Colorimeter), to provide a concentration of test microorganisms of approximately 
1×108	colony-forming	units/ml	(CFU/ml).	All	bacteria	were	passed	through	5	μm	
filters (Pall Corporation, USA) to avoid clustering.
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Figure 1. L. acidophilus cultured on Lactobacilli MRS medium.
3.3.2 Neutralizing solution
Neutralizing solution was added to the mixture of bacteria and antimicrobials to 
stop the antiseptic action. Neutralizing solution, containing 1% (w/v) peptone, 
3% (w/v) Tween 80 (BDH, Poole, UK), 0.3% (w/v) lecithin (Fisher Scientific, 
Loughborough, UK), 0.1% (w/v) histidine (BDH) and 0.1% (w/v) cysteine (Sigma-
Aldrich) was prepared in dH2O and sterilized.
3.3.3 Evaluation of bactericidal activity
The bactericidal activity of the anti-microbials was tested by the quantitative 
suspension	method	(Figure	2).	Briefly,	50	μl	aliquots	of	the	test	suspensions	of	
microorganisms with cell titer 1.0×108	CFU/ml	were	exposed	to	450	μl	of	each	
antiseptic (PHMG-P or CHX), at concentrations of 0.05, 0.2, 0.5, and 1% for 30 s, 
1,	3	and	5	min,	followed	by	transfer	of	the	mixture	to	450	μl	of	neutralizing	solu-
tion. After 10 min neutralization, serial dilution (10-3, 10-4, and 10-5) was performed 
and	100	μl	aliquots	were	plated	on	the	appropriate	media	and	incubated	at	37˚C	
for 2 to 7 days, depending on the bacterial species. The colonies were counted to 
assess the viability of the test mixture. Antiseptic activity was evaluated as the 
reduction factor (RF), calculated as the difference between logarithms of CFU/ml 
values before and after exposure to tested concentrations of the antiseptics. The 
sensitivity threshold of the method was estimated to be 1.0×103 CFU/ml. If the 
antiseptic application resulted in total suppression of bacteria, defined as no growth 
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state, cell titer was presumed to be under 1.0×103 CFU/ml. For each product and 
time of exposure, the bactericidal effect of the antiseptic agents against the test 
species was recorded in duplicate during two consecutive runs.
Figure 2. Flow diagram of the quantitative suspension method for testing bactericidal 
activity.
3.3.4 Cell culture
For Paper II human gingival fibroblasts (HGF) were isolated from gingival biopsies 
and cultured as previously described, or purchased from CLS Cell Lines Service 
GmbH, Eppelheim, Germany [17]. Minced gingival explants were transferred to 
25 cm3 Falcon tissue culture flasks containing 5ml of DMEM (Invitrogen Life 
Technologies, Scotland, UK) supplemented with 4mM L-glutamine, 50 units/ml 
penicillin,	50	μg/ml	streptomycin	and	5%	foetal	calf	serum	(Invitrogen,	Scotland,	
UK). The fibroblasts were cultured at 37ºC in a humidified incubator with 5% CO2 
and routinely passaged at 80% confluence, using 0.025% trypsin in PBS containing 
0.02% EDTA (Invitrogen, Scotland, UK). Cells sampled from passages 10 to 14 
were subsequently used in the studies.
3.3.5 Cell viability test 
The effect of the antiseptics on fibroblast viability was estimated colorimetrically 
by tracing live cells in culture as described by Mosmann (76). The assay is based on 
the ability of living cells to take up and convert tetrazolium bromide to formazan 
in oxidoreductive mitochondrial processes (Fig 3). 
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Figure 3. Human gingival fibroblasts after the first step of the cell viability test. Vital 
spindle-like fibroblasts are coloured blue due to the formazan pigmentation (a). Non-vital 
HGF were unable to uptake and process tetrazolium bromide (b), magnification x20.
HGF were seeded on 96-well tissue culture plates at a concentration of 1×104 cells/
well and cultivated for 24h. The cells were rinsed twice with serum-free DMEM, 
followed by the addition of serum-free medium containing PHMG-P or CHX at 
concentrations of 0.00005, 0.00009, 0.0005, 0.0009, 0.005, 0.009, 0.05, 0.1, 0.2, 
0.5 and 1% (w/v). The cells were incubated for another 24h prior to determination 
of cell viability, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay in accordance with the manufacturer’s instructions (Abnova, 
Taipei, Taiwan). Cells killed with saponin were used as a negative control. The 
cells were also treated with PHMG-P or CHX at 0.005, 0.05, 0.1, 0.2, 0.5 and 1% 
(w/v) concentrations for 1, 3, 15 and 30 min. The fibroblasts were rinsed twice 
with media supplemented with serum and analyzed for cell viability. The OD of 
the reaction product was measured by spectrophotometry (Labsystems Multiskan 
MS, Helsinki, Finland) at 540 nm. Cell viability was then scored according to the 
following formula: Cell viability (%) = (OD of the test group – OD of the positive 
control)/(OD of the negative control group – OD of the positive control) x 100. All 
cell culture experiments were carried out in quadruplicate in two independent series.
3.3.6 Stimulation of gingival fibroblasts with IL-1β
The effects of PHMG-P and CHX on the pro-inflammatory molecules PGE2, IL-6, 
IL-8 and collagenase MMP-1 secreted by gingival fibroblasts were assessed in 
non-stimulated	cells	and	in	cells	stimulated	with	IL-1β.	HGF	were	seeded	at	a	con-
centration of 5×105 cells/well on 24-well plates. Following overnight incubation, 
the cells were rinsed twice with serum-free media and treated with the antiseptics 
CHX and PHMG-P at the respective concentrations 0.000045% and 0.00009% 
(w/v)	separately,	or	in	combination	with	IL-1β	(300pg/ml)	(R&D	Systems	Inc.,	
Minneapolis,	USA)	for	24h.	Serum-free	DMEM	or	IL-1β	served	as	negative	and	
positive controls, respectively. The conditioned media supernatants were collected 
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and stored at –80°C for further analysis. The PGE2, IL-6, IL-8 and MMP-1 levels in 
the supernatants were determined using commercial enzyme-linked immunosorb-
ent assay (ELISA) kits for PGE2 (Cayman Chemical, Ann Arbor, USA), IL-6, IL-8 
and MMP-1 (R&D Systems Inc., Minneapolis, USA) according to the manufac-
turer’s instructions. Absorbance values were recorded at 450 nm by a microplate 
spectrophotometer (Labsystem Multiskan MS) with wavelength correction at 540 
nm. Each antiseptic treatment was performed and analyzed in triplicate.
3.3.7 Biomarker Immunoassays
The	levels	of	IL-1β,	IL-8,	IL-10	and	IL-17A	were	determined	using	multiplex	
immunoassay, according to the manufacturer’s instructions (ProcartaPlexTM 
Multiplex Immunoassay, ThermoFisher, Vienna, Austria). The readings were 
recorded using Bio-Plex 100 (Bio-Rad Laboratories, Inc., CA, USA). The assay 
ranges	were	as	follows:	for	IL-1	β:	0.32-1330	pg/mL;	for	IL-10:	0.18-750	pg/ml	
and for IL-17A: 0.25-1030 pg/ml.
MMP-8 levels were measured by time-resolved immunofluorimetric assay (IFMA) 
as described earlier (77, 78). Briefly, the MMP-8 specific monoclonal antibod-
ies 8708 and 8706 (Medix Biochemica, Kauniainen, Finland) were applied as 
a capture antibody and a tracer antibody. The tracer antibody was labelled with 
europium-chelate and the assay buffer contained 20 mM Tris-HCl (pH 7.5), 0.5 
M NaCl, 5 mM CaCl2,	50	μM	nCl2, 0.5% bovine serum albumin, 0.05% sodium 
azide and 20 mg/l diethylenetriaminepentaacetic acid. GCF samples were diluted 
in assay buffer and incubated for 1 h, followed by another 1 h of incubation with 
tracer antibody. Enhancement solution was added and incubation fluorescence was 
measured after 5 min, using a 1234 Delfia Research Fluorimeter (Wallac, Turku, 
Finland). The detection limit for this assay was 0.08 ng/ml.
Due to the heterogeneity of the samples i.e. variation in human material because 
of manual sampling, GCF samples were normalized to a total protein concen-
tration. The total concentration of proteins was measured in each sample using 
a fluorescence-based assay according to the manufacturer’s instructions (Qubit 
Fluorimeter, Life Technologies, USA). Immune marker concentrations were 
adjusted to total protein concentration and expressed as a ratio (pg of immune 
marker/mg of total protein). 
3.3.8 DNA extraction and quality control
DNA was extracted from clinical samples using a “Nucleosorb-C” kit (Primetech, 
Minsk, Belarus) according to the manufacturer’s instructions. DNA quality and 
concentration were estimated by spectrophotometry at wavelengths of 260/280 
nm,	260/230	nm,	260/320	nm	(SOLAR	РВ2201,	Minsk,	Belarus).	The	majority	
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of samples reached values of 260/280 = 1.7-1.9 and molar concentration >5 ng/µl. 
Finally, some DNA samples were analyzed with 1% agarose gel electrophoresis 
to evaluate the degree of fragmentation (formaldehyde was not added to avoid 
denaturing).
3.3.9 Primers and probes for real time PCR
Oligonucleotide sets, including probes developed and validated by other researchers, 
were used in this study (Table 1) (79-82). To optimize the reaction and increase its 
efficiency, some sequences were adjusted (Table 1). They were partially modified 
with locked nucleic acid (LNA) nucleotides. In each case, we selected the ratio of 
oligonucleotides in the reaction mixture, and optimized the buffer conditions to 
predict and avoid formation of secondary structures revealed by “The mfold Web 
Server” and “Oligoanalyzer” (Integrated DNA Technologies, Inc., USA) (83, 84). 
The oligonucleotide sequences and modifications are shown in Table 1.
Table 1. Oligonucleotide sequences used in related research and our modifications.
Species Sequences Our modifications
P. gingivalis  
(81)
Forward TGGTTTCATGCAGCTTCTTT
Reverse TCGGCACCTTCGTAATTCTT
Probe FAM-
CGTACCTCATATCCCGAGGGGCTG-BHQ1
-
-
-
T. denticola  
(81)
Forward CCTTGAACAAAAACCGGAAA
Reverse GGGAAAAGCAGGAAGCATAA
Probe FAM-
GAGCTCTGAATAATTTTGATGCA-BHQ1
-
-
-
F. nucleatum 
(80)
Forward GGATTTATTGGGCGTAAAGC
Reverse GGCATTCCTACAAATATCTACGAA 
Probe FAM-CTCTACACTTGTAGTTCCG 
GG[LNA-A]
TTTATTGGGCGTAAAGC 
-
CTCTACACTTGTAGTT[LNA-C]
[LNA-C]G 
T. forsythia  
(82)
Forward GAGGTTGTGGAAGGTATG 
Reverse GTAGATCAGAATGTACGGATT
Probe 
FAM-TCTCCGCTTATTTCGTGAC-BHQ1
-
-
-
A. actinomyce-
temcomitans 
(82)
Forward GCGAAACGAAGAGAAGCAAG
Reverse CCTACCCAACAGGCGTATCA
Probe FAM-ATTCCCAACCGCACTT-BHQ1
-
-
FAM-ATTCCCAAC[LNA-C]
GCACTT-BHQ1
P. intermedia 
(79)
Forward TGTCGGTTTACTGGCTATGTTCTC
Reverse CTTGTCTGTTGGCCATCTTGAAG
Probe FAM-
TCAAAGACGCACGTACCAATCCAGACC-
BHQ1
-
-
-
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3.3.10 Real time PCR 
Real time PCR was conducted by CFX96touch (Bio-Rad, USA) according to the 
following protocol. The reaction mix (25 µl volume contained: 500 nM of each 
oligonucleotide, including the probe, 2 mM MgCl2, 0.1 mM of each dNTP, 1x PCR 
commercial buffer without MgCl2, 1.25 U of thermostable Taq DNA-polymerase 
without hot start, deionized RNAse/DNase free water for PCR. The cycling con-
ditions were: +95oC for 3 min – primary denaturation, then 50 cycles: +95oC for 
10 s and +60oC for 59 s (annealing and elongation steps).
3.3.11 Standard curves and reaction efficiency 
To plot standard curves for microbes the mixture of 10 different DNA samples was 
used with the highest concentrations resulting from DNA purification. Before DNA 
purification, each sample was collected from a separate patient. This approach is 
intended to minimize the effect of the sample type and the isolation method on 
the reaction efficiency.
Quantitation cycle (Cq) values were determined in DNA samples and those with 
Cq < 20 were selected. The DNA was then pooled and mixed in one tube, vortexed 
and serially diluted 5-fold. This yielded 5 calibrators with 5-fold steps of DNA 
concentration. The data on reaction efficiency and R2 parameters are presented in 
Table 2. In all cases the recorded R2 values exceeded 0.99, which is consistent with 
the data reported in the literature. At the same time, in most of our experiments the 
recorded efficiency of the reactions was superior to that of previous studies.  
Table 2. Comparison of reaction efficiency and R2 values of the present study with 
the previous literature data.
Target species Eff. 
(current)
Eff. 
(previous)
R2 
(current)
R2  
(previous)
P. gingivalis 96.5% 91.0% (81) 0.997 0.999 (81)
T. denticola 99.3% 7.0% (81) 0.998 1.000 (81)
F. nucleatum 99.7% 90-100% (85) 0.996 0.997 (85)
T. forsythia 97.0% 88.0% (82) 0.998 1.000 (82)
A. actinomycetemcomitans 93.5% 73.7% (82) 0.999 0.999 (82)
P. intermedia 95.6% 121.2% (79) 0.994 0.995 (79)
SCARNA5 97.8% - 0.998 -
3.3.12 PCR data analysis
Heterogenic microbial DNA samples were normalized by human SCARNA5 (ID: 
677775) NC_000002.12 gene. The gene possesses a DNA sequence which is not 
replicated in multiple copies in the human genome and does not contain specific 
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sites for microbial oligonucleotide annealing. The oligonucleotide sequence was 
designed on primer 3 v. 0.4.0 and a subsequent analysis with mfold and IDT 
Oligoanalyzer (86-88). The resulting oligonucleotide sequences are Forward 
CCTCCCGTCACATTTAAGTCA; Reverse GCCGATCACTCTCAGAAACAC; 
Probe FAM-TCATGGAGCAGCTGATAATTTG-BHQ1.
Using a cell culture of human keratinocytes, we made approximate counts of human 
SCARNA5 gene copies for each amplification cycle during standard curve plot-
ting, using only human DNA with known concentrations. The reaction efficiency 
differed slightly between the clinical samples and the cell culture (97.8% and 
98.9% respectively) as well as R2 0.998 and 0.992, respectively.
Cq equal to 25 of 21.4 ng/µl corresponded to 35780 copies per reaction in the run 
graph. The difference of 1.2% in reaction efficiency was negligible.
The number of SCARNA5 copies in each clinical sample was calculated using 
quantitative calibration. The number of copies of the microbial genome-equivalents 
was then computed for each target, based on corresponding copies at the start of 
each amplification cycle. The obtained data were used for further statistical analysis.
Real time PCR data were analyzed using BioRad CFX96touch basic software. 
The obtained Cq data were converted to MS Excel format for subsequent analysis. 
Due to gentle collection technique the samples contained insufficient amount of 
human material for normalization. The absolute number of microbial gene equiva-
lents is further presented, analyzed and discussed. 
3.4 Clinical study 
3.4.1 Clinical study design
The study was a single center, double-blind randomized prospective clinical trial. 
To avoid selection bias, a simple randomization technique based on the throw of 
a dice was used. All patients were allocated to one of 3 groups according to the 
score on the dice cast by the nurse: scores 1 or 4 went to the first group, 2 or 5 to 
the second group and scores 3 or 6 to the third group. In the first group (19 sub-
jects) Aquin (Inkraslav©, PHMG-P 1%), was applied as an adjunctive irrigant for 
SRP; in the second group (21 subjects) the irrigant used was 0.2% CHX (Public 
Pharmaceutical Service, Minsk, Belarus), and the third group (19 subjects) served 
as the control, with distilled water irrigation.
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3.4.2 Patient enrolment, examination and treatment
The participants were recruited into the study between autumn 2011 and spring 
2014 from patients referred to the Periodontal Clinic of the School of Dentistry, 
Belarusian State Medical University. The inclusion criteria stipulated that the sub-
jects should be aged 18 to 75 years, possess normal health status, with diagnosed 
generalized or local severe chronic periodontitis, have at least 3 teeth with peri-
odontal pockets of minimum probing depth of 6 mm, and radiographic evidence 
of	extensive	bone	loss	(≥	one	third	of	root	length).	In	compliance	with	a	new	clas-
sification	system	for	periodontal	and	peri‐implant	diseases	and	conditions,	such	
a condition is referred to as chronic periodontitis stage III or IV grade B (1). The 
Armitage 1999 diagnostic keys and definitions were used as they were widely 
applied at the time of the study (6). The reasons for exclusion from this study, 
apart from failing to meet the aforementioned criteria, were as follows: periodontal 
treatment performed less than six months prior to the study, pregnancy, nursing 
mother, symptoms which might affect progression of periodontal disease or which 
require administration of antibiotics, allergy to CHX, PHMG-P, or a course of 
antibiotics in the previous 6 months. 
At baseline the patients underwent a comprehensive periodontal examination. 
Panoramic radiographs were used to verify the diagnosis of chronic severe peri-
odontitis. The presence of dental plaque at the gingival margin along the mesial, 
buccal, distal and lingual aspects was determined, and the plaque index (PI) was 
calculated. Gingival inflammation was registered as bleeding on probing (BOP) 
and expressed as the proportion of bleeding sites relative to the total number of 
sites. Pocket probing depth (PPD), regarded as the primary outcome, was meas-
ured to the nearest mm using a calibrated Williams’ periodontal probe (Falcon®, 
Sialkot, Pakistan). PPD was defined as the distance between the gingival margin 
and the deepest point of probe tip penetration into the periodontal pocket at six sites 
measured on each tooth. Periodontal pockets with PPD > 4 mm were considered 
to be pathological and were selected for analysis (89). PPD of 6 mm was chosen 
as the threshold value for surgical treatment need. After the baseline examination, 
all subjects received initial periodontal therapy, which included motivation, oral 
hygiene instruction and full-mouth debridement, using a combination of ultrasonic 
and manual instrumentation, with one of the test solutions as an irrigant. The irri-
gants were delivered to the periodontal pockets at a dose of 2 ml per periodontal 
pocket, by means of a syringe with a blunt needle. At each follow-up appoint-
ment, all treatment procedures were repeated. After baseline, five follow-ups were 
scheduled: at 2 weeks and 1 month, and then at 4, 6 and 12 months. 
Full mouth debridement with adjunctive irrigation took up to two hours. Scaling 
was performed with the help of universal curettes, by adjusting 2 mm of the tip 
and stroking twice per each mm of the root. Over the period of the study subse-
quent appointments for debridement were less time-consuming, as the scaling 
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need decreased. Local anesthetics were used if necessary, e.g. Ubistesin® (3M 
ESPE, Seefeld, Germany). All irrigant solutions were prepared by a nurse, who 
randomly chose the code and distributed the solutions in identical opaque bot-
tles with corresponding numbers. The legend was sealed until statistical analysis.
3.4.3 Collection of GCF and bacterial samples
For Paper IV gingival crevicular fluid (GCF) and bacterial samples were collected 
from patients participating in the clinical trial (Paper III) at baseline, at 2 weeks, 
1 and 4 months.
In order to avoid bleeding GCF samples were taken before clinical examination 
and bacterial sampling. Each tooth was isolated with cotton rolls and air dried. The 
contents of the periodontal pockets were extracted by paper strips PerioPapers® 
(Oraflow Inc., NY, USA) inserted for 30 s into 4 periodontal pockets, one from each 
quadrant. The same periodontal pockets were used for sampling at each follow-up. 
Strips contaminated with blood were discarded. The strips were placed separately 
in empty test tubes, immediately frozen at -20°C, transferred to a freezer within 
a week and maintained at -80°C until further processing.
Bacteria were sampled by scaling from the deepest 4 periodontal pockets, each 
representing a quadrant of the dentition. In order to harvest similar-sized samples 
from each pocket, 2 strokes of the scaler were made in each pocket. The content 
was then pooled in a test tube filled with sterile transport medium and frozen at 
-20˚C	until	DNA	extraction.	
3.5 Statistical analysis
The data from patients (Paper III) were analyzed as they were randomized. If the 
patient withdrew from the study the data were stored and analyzed for the actual 
period. Descriptive statistical data were computed and expressed as the mean ± 
standard deviation (SD). The Friedman Test was applied to reveal differences 
within treatment groups and the Kruskal-Wallis Test was applied for intergroup 
comparisons. To estimate the significance of differences between two groups, the 
Mann-Whitney Test was applied to independent groups and Wilcoxon Signed 
Rank Test to dependent groups. To evaluate the interrelationship of the observed 
parameters Spearman’s rank correlation coefficient was chosen. P-value = 0.05 
was defined as statistically significant. In order to achieve 80% power in detect-
ing an average inter-group PPD difference of 1 mm (assumed SD ± 1.5 mm) the 
minimum sample size was estimated to be 14 patients in each group. Oversampling 
was planned to allow for possible withdrawals and data corruption.
Data processing was conducted using the software packages GraphPad Prism 6 
(GraphPad Software, San Diego, California USA) for Paper II and SPSS Statistics 
25 (IBM©, SPSS© Statistics, NY, USA) for Papers III and IV.
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4 RESULTS AND DISCUSSION
4.1 Activity of clinically relevant working concentrations 
of CHX and PHMG-P against standard quality control 
microorganisms
Mature biofilm exhibits enhanced tolerance for antimicrobial agents and the ini-
tial proposal was to determine antimicrobial activity on biofilm, rather than on 
planktonic bacteria (15). However, to date there is a lack of standardized methods 
for such assays on biofilm. Moreover, biofilm properties differ, depending on the 
surrounding environment. For example, Acinetobacter baumannii shows different 
resistance profiles in laboratory media and on ex vivo human ascites (90). In the 
present study the bactericidal effects of PGMG-P and CHX were tested on cultures 
of standard bacterial species, periodontopathogenic and cariogenic bacteria, using 
the quantitative suspension method. The results are summarized in Figures 4-7.
Clinically relevant working concentrations of PHMG-P (1%) and CHX (0.2%) 
exhibited similar patterns of antimicrobial activity against standard quality control 
microorganisms (S. aureus, E. coli, P. aeruginosa and C. albicans) (Fig 4). 1% 
PHMG-P and 0.2% CHX exerted rapid bactericidal effects on all species within 30 s 
of exposure and reduced the bacterial titer to below the detection limit (RF over 5).
Figure 4. Antimicrobial activity of clinically relevant working concentrations of PHMG-P 
(1%) and CHX (0.2%) against standard quality control microorganisms (S. aureus, Е. coli, 
P. aeruginosa and C. albicans).
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4.2 Activity of clinically relevant working concentrations 
of CHX and PHMG-P against periopathogens and 
cariogenic microorganisms
Both tested antiseptics PHMG-P and CHX at working concentrations 1 and 0.2%, 
respectively, exerted a rapid bactericidal effect (within 30 s) against A. actinomy-
cetemcomitans and P. gingivalis (Fig 5). In contrast to the periopathogens, stricter 
PHMG-P and CHX application modes were required to control cariogenic bacteria. 
Even after 5 min of treatment, neither 1% PHMG-P nor 0.2% CHX were able to 
eliminate L. acidophilus (Fig 5). Exposure of thirty seconds to 1% PHMG-P or 
0.2% CHX failed to achieve a significant reduction in the S. mutans count, with 
RF values equaling 2.3 and 3.88, respectively. (Fig 5). Following prolonged treat-
ment, up to 3 min, working concentrations of the antiseptics completely inhibited 
S. mutans (RF 5.8 and 5.73, respectively). 
Figure 5. Antimicrobial activity of clinically relevant working concentrations of PHMG-P 
(1%) and CHX (0.2%) against periopathogens and cariogenic microorganisms (P. gingi-
valis, A. actinomycetemcomitans, S. mutans and L. acidophilus).
22
4.3 Activity of diluted CHX and PHMG-P against 
 standard quality control microorganisms
Once introduced into the oral cavity, antiseptics are gradually diluted in saliva and 
their activity tends to decline over time (91). Thereafter, antiseptics, even at low 
concentrations, display protracted effects until inactivation. Therefore, it appears 
logical that antimicrobial activity should be evaluated not only in the range of clini-
cal working concentrations of antiseptics but also at several dilutions and different 
periods of exposure. The bactericidal effects of antiseptics should be assessed for 
4-20 fold dilutions and a relevant time span of 30 s to 1-5 min. 
Diluted to 0.05% concentration, neither antiseptic was able to eliminate S. aureus, 
E. coli, P. aeruginosa and C. albicans after exposure of 30 s (Fig. 6). Prolonging 
treatment time for 3 min resulted in a strong bactericidal effect against S. aureus and 
E. coli, accompanied by a pronounced fall in microbial titer, below the sensitivity 
threshold of the method. This study demonstrated that with prolonged exposure, 
antiseptics even at dilutions of 4-20-fold, exerted antimicrobial activity against 
oral microorganisms in vitro. Exposure to 0.05% PHMG-P totally eliminated P. 
aeruginosa and C. albicans within 3 min, whereas 0.05% CHX produced the same 
effect within 5 min (Fig 6).
Figure 6. Antimicrobial activity of highly diluted PHMG-P (0.05%) and CHX (0.05%) 
against standard quality control microorganisms (S. aureus, Е. coli, P. aeruginosa and 
C. albicans).
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4.4 Activity of diluted PHMG-P and CHX against 
 periodontopathogenic and cariogenic bacteria
Highly diluted PHMG-P (0.05%) and CHX (0.05%) acting for 30 s exhibited 
milder impact on A. actinomycetemcomitans and P. gingivalis, characterized by 
RF values under 4 (Fig 7). For both antiseptics, prolonging exposure to 3 min 
resulted	in	total	elimination	of	the	bacteria	(RF	≥	5.86).
L. acidophilus culture was not critically affected by the antiseptics at 0.05% con-
centrations after 5 min exposure. PHMG-P and CHX caused only a minor drop in 
microbial titers, with RF values 0.24 and 0.51, respectively (Fig 7). 
The limited antimicrobial impact on S. mutans following 30 s exposure to 0.05% 
PHMG-P or CHX action is reflected in the respective RF values - 0.28 and 
0.99 (Fig 7). Longer exposure (3 min) to 0.05% PHMG-P and 0.05% CHX also 
demonstrated insufficient antimicrobial activity (RF 3.55 and 3.73, respectively). 
Prolonged exposure (5 min) diminished S. mutans titer below the sensitivity 
threshold of the method.
Figure 7. Antimicrobial activity of highly diluted PHMG-P (0.05%) and CHX (0.05%) 
against periodontopathogens and cariogenic bacteria (P. gingivalis, A. actinomycetem-
comitans, S. mutans and L. acidophilus)
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Strong bactericidal activity of 1% PHMG-P expressed within 30 s against P. gingi-
valis and A. actinomycetemcomitans and the activity retained after 20-fold dilution 
and exposure of 3-5 min suggests that PHMG-P may be a promising antiseptic for 
periodontal disease management and prophylaxis. According to our data, PHMG-P 
at a concentration of 0.05% required 3 min to achieve bactericidal effects against 
the majority of bacteria. Owing to the potent biocidal activity expressed within a 
short time against S. mutans, S. aureus, C. albicans, as well as toward other qual-
ity control microorganisms and potential dental plaque constituents, PHMG-P 
warrants evaluation for application in caries prevention. 
4.5 Effect of PHMG-P and CHX on viability of human 
gingival fibroblasts 
When assessing prospects of antiseptic agents for clinical application, not only 
antimicrobial activity but also possible cytotoxicity to human tissues must be 
taken into account. The effects of antiseptics on human gingival fibroblasts were 
investigated in terms of the number of vital cells remaining after exposure to the 
antiseptic for either 24 h or 1-30 min.
Initially we determined the maximum non-toxic concentration of the antiseptics 
that is, the concentration above which exposure of 1 min to the antiseptic could 
be lethal to cells. The maximum concentration of antiseptics not fatal to HGF was 
0.005% (Fig 8A). This value is in fact lower than those applied in clinical medi-
cine (0.05-1%) and those exhibiting antimicrobial activity in our previous study 
(0.05%) (92). However, in vitro gingival fibroblast culture does not faithfully 
replicate the environment in the human oral cavity, where protection is provided, 
not only by epithelial cells but also by saliva, which gradually dilutes the concen-
tration of the antiseptics (93). This concentration was selected for testing during 
a prolonged exposure period of 1 to 30 min. Five min of contact with 0.005% 
PHMG-P caused loss of cellular vitality, whereas cells survived even after 30 min 
exposure to 0.005% CHX (Fig 8B).
Long-term exposure (24 h) of cells to PHMG-P at concentrations higher than 
0.00009% resulted in loss of fibroblast vitality. In contrast, inhibition of fibro-
blasts by CHX occurred at concentrations higher than 0.0009% (Fig 8C). PHMG-P 
severely disrupted fibroblast survival during 24 h exposure at concentrations ten 
times lower than CHX, demonstrating a stronger cytotoxic effect than the gold 
standard, CHX. The greater cytotoxic potential of PHMG-P compared with CHX 
may be attributed to its polymeric structure, which enhances adherence of the 
antiseptic to the tissue surface (94, 95). 
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An outbreak of fatal idiopathic lung disease has been reported in South Korea 
(96). The suspected cause was chronic inhalation of a humidifier disinfectant (96). 
The disinfectant mixture included PHMG-P, poly (oxyalkylene guanidine) hydro-
chloride (PHMG-H), and 5-chloro-2-methylisothiazol-3(2H)-one/2-methyliso- 
thiazol-3(2H)-one) (97). Extension of the application scope from disinfectants to 
humidifier water treatment changed the route of administration (98). Modified 
manner of exposure might alter the health effects of substances. In an animal 
model, chronic exposure to lower concentrations of PHMG-P aerosol particles 
(1.5 mg/m3) might be responsible for pulmonary inflammation and fibrosis, while 
alimentary delivery of PHMG-P at a higher concentration (40 mg/kg/day) showed 
no-observed-adverse-effect levels (NOALs) (98, 99). PHMB is not absorbed when 
applied topically (100). One study questioned the role of PHMG-P as the cause 
of lung disease in Korean residents. However, this investigation could be biased, 
since it was financed by the manufacturer of humidifier (101). Unfortunately, 
after an interval of several years, new cases of clinically similar lung pathologies 
have been reported in South Korea. The putative causative agents are two new 
substances used as humidifier disinfectants: (5-chloro-2-methyl-4-isothiazolin-
3-one (CMIT) and/or 2-methyl-4-isothiazolin-3-one (MIT)) (102).
Multidisciplinary experts considering the results of genotoxicity and animal 
studies concluded that carcinogenic risk from application of PHMB for wound 
antisepsis can be ruled out (100). An expert meeting in 2008 recommended pol-
yhexamethylene biguanide (PHMB) as a highly appropriate antiseptic agent for 
treatment of infected wounds (103). Moreover, on the basis of clinical evidence, 
experts supported the use of PHMB as an antiseptic for wound treatment (100). It 
was mentioned earlier, that local application of PHMG-H as a mouthrinse showed 
good clinical results (74).
In the EU, a similar humidifier disinfectant is marketed commercially under the 
brand Akacid Plus® (104). In in vitro studies Akacid plus demonstrated a broad 
spectrum of antimicrobial properties and in vivo, animal models showed low oral 
and dermal toxicity (105). Its nebulization efficiently removed pathogenic noso-
comial microorganisms (106). To the best of our knowledge there are no reports 
of idiopathic lung diseases associated with Akacid Plus. Topical application of 
0.5% Akacid Plus cream was efficient in the treatment of methicillin-resistant 
Staphylococcus aureus superficial skin infection in a guinea pig model (107). It 
has been also shown that Akacid medical formulation induced apoptosis in leu-
kemic cells in vitro and inhibited tumor growth in vivo (108).
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Figure 8. The effect of PHMG-P and CHX on viability of human gingival fibroblasts. A. 
Viability of human gingival fibroblasts after 1 min exposure to PHMG-P and CHX in the 
concentration range 0.005-1%. B. Dynamics of gingival fibroblast viability after 30 min 
treatment with either 0.005% PHMG-P or 0.005% CHX. C. Survival rate of human gingival 
fibroblasts after 24 h exposure to 0.00005-0.05% of PHMG-P and CHX.
4.6 Modulatory effect of PHMG-P and CHX on the 
secretion of inflammatory mediators and MMP-1 
by human gingival fibroblasts
Human	gingival	fibroblasts	were	stimulated	with	IL-1β	to	induce	an	inflammatory	
response. The effects of antiseptic administration (PHMG-P and CHX) were then 
monitored, by assessing the secretion of PGE2, IL-6, IL-8 and MMP-1. PHMG-P 
or CHX alone did not affect the levels of PGE2, IL-6, IL-8 or MMP-1 whereas, as 
expected,	stimulation	with	IL-1β	resulted	in	considerably	increased	production	
of all four mediators, compared with untreated cells (p<0.0001) (Fig 9A-C). The 
addition	of	PHMG-P	or	CHX	along	with	IL-1β	significantly	reduced	the	levels	
of PGE2 (p<0.001), as well as IL-6, IL-8 and MMP-1 synthesis by fibroblasts 
(p<0.05) at all the concentrations tested (Fig. 9A-D).
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Since the experiments assessing anti-inflammatory properties of antiseptics require 
overnight incubation, it is necessary to use concentrations which are low enough 
for the cells to withstand exposure for 24 h. In the experiment only low concen-
trations of antiseptics expressed anti-inflammatory properties: if high concentra-
tions are used, the cells might perish before the anti-inflammatory properties can 
be expressed. On the other hand, the higher concentrations are applied, the more 
powerful is the resultant anti-inflammatory effect. In case of chaotropic mole-
cules, the more molecules are available, the more molecules of pro-inflammatory 
mediators will be bound, resulting in a more pronounced anti-inflammatory effect. 
This	might	also	be	true	when	antiseptics	bound	to	IL-1β	in	the	treatment	cocktail	
partially neutralized the cytokine and, consequently, inflammation in cells was 
promoted	to	a	lower	extent	compared	with	IL-1β	only.	This	aspect	could	be	verified	
in future experiments by adjusting the study design and using separate sequential 
treatment. However, even in this case antiseptics could decrease concentration of 
cytokines in periodontal pockets. 
The present study showed that at low concentrations PHMG-P and CHX exhibited 
immunomodulatory activity. Röhner et al. have previously reported the ability of 
PHMB but not CHX to induce morphological cell damage after a short exposure 
time, resulting in the secretion and accumulation of pro-inflammatory cytokines 
and	chemokines,	such	as	IL-1β,	IL-6,	IL-7	and	TNF-α	(109).	Conversely,	in	the	
present study neither PHMG-P nor CHX provoked an inflammatory response by 
the	gingival	cells.	Moreover,	treatment	of	IL-1β-stimulated	human	gingival	fibro-
blasts with non-toxic concentrations of both PHMG-P and CHX led to statistically 
significant reductions of PGE2, IL-6, IL-8 and MMP-1 levels. Some antibiotics have 
previously been implicated in downregulating the expression of pro-inflammatory 
cytokines IL-6, IL-8 and MMP-1 by fibroblasts (110). 
Inactivation of early phase inflammatory cytokines by CHX or PHMG-P may 
arrest	the	progression	of	periodontal	diseases.	However,	Türkoĝlu	et	al.	failed	to	
confirm a correlation between clinical improvement and diminished production 
of cytokines in GCF after CHX treatment (111).
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Figure 9. The effect of PHMG-P and CHX on the secretion of inflammatory mediators by 
human gingival fibroblasts. The levels of PGE2 (A), IL-6 (B), IL-8 (C) and MMP-1 (D) 
secreted by non-stimulated or IL-1β-stimulated human gingival fibroblasts after treatment 
with PHMG-P or CHX (0.000045% and 0.00009%, respectively) were assessed in cell 
supernatants by ELISA. Media – media only, CHX45 – CHX 0.000045%, CHX90 – CHX 
0.00009%, PHMG-P45 – PHMG-P 0.000045 % and PHMG-P90 – PHMG-P 0.00009%.
4.7 Clinical study results
Fifty-nine patients (30 males and 29 females) with severe chronic periodontitis, 
aged 29 to 70 years, mean age 47.2 (SD 11.2) years were enrolled in the study. 
The demographic data are presented in Table. 4. Fifty-three patients completed the 
study; six withdrew, resulting in an overall retention rate of 89.8 %. The details 
are summarized in the flow diagram (Fig 10).
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Enrollment
Assessed for eligibility (120)
Randomized (59)
Not meeting inclusion criteria (60)
Declined to participate (1)
PHMG-P (19) CHX (21) Water (19)
Samples collection
Loss at follow up (6):
• Discontinued from PHMG-P group (3)1
• Discontinued from CHX group (2)2
• Discontinued from CHX group (1)3
Treatment: Oral Hygiene instructions,
Full mouth debridement with irrigation 
Analysis 
Baseline
GCF* 16 Bac** 14
Baseline
GCF 19 SB 15
Baseline
GCF 12 Bac 11
2 weeks
GCF 14 Bac 13
2 weeks
GCF 18 SB 16
2 weeks
GCF 12 Bac 12
1 month
GCF 14 Bac 14
1 month
GCF 18 SB 13
1 month
GCF 12 Bac 13
4 months
GCF 11 Bac 14
4 months
GCF 14 SB 14
4 months
GCF 10 Bac 11
*GCF – The number of gingival crevicular
fluid samples was adjusted to the number of 
patients
**Bac – the number of subgingival biofilm 
samples
6 months 6 months 6 months
12 months 12 months 12 months
Figure 10. Flow Diagram. 
Table 4. Demographic data 
Variables PHMG-P CHX Water Total
Enrolled volunteers number 19 21 19 59
Number of patients completing the 
study 16 19 18 53
Average age (SD) 46.9±11.4 49.4±12.3 45.4±9.8 47.3±11.2
Male 10 9 11 30
Female 9 12 8 29
Smoking addicts 1 2 6 9
The number of periodontal 
pockets measured initially
≥ 4 mm 359 444 422 1225
≥ 6 mm 245 250 243 738
The number of periodontal pockets 
around anterior teeth 118 (32.9%) 209 (47.1%) 187 (44.3%) 514
At baseline, there were no intergroup differences in PI and BOP (p>0.05), hence 
the groups were comparable (Table 5). In the course of the study PI and BOP val-
ues improved significantly within all three groups (p<0.05), indicating that oral 
debridement and hygiene caused similar effects in all the test subjects. No inter-
group differences in PI and BOP were observed at any follow-up  examination, 
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implying a weak antiseptic effect on PI and BOP. This might be due to brief and 
sporadic exposure to the antiseptics during debridement, possibly resulting in 
minor improvement, below the clinically detectable threshold. Moreover, anti-
septic solutions could be rapidly washed out of periodontal pockets by gingival 
crevicular fluid (112). Another plausible explanation is that pathophysiological 
mechanisms governing the parameters PI and BOP are not sensitive to the impact 
of antiseptic solutions.
Table 5. Oral hygiene and bleeding on probing before and after treatment. 
Treatment 
Group
PI, % (Mean±SD) BOP, % (Mean±SD)
Baseline 1 
month
4 
months
6 
months
12 
months
Baseline 1 
month
4 
months
6 
months
12 
months
PHMG-P 35±24 20±18 26±17 22±18 16±13 33±22 15±16 16±15 12±09 7±7
CHX 33±26 16±13 15±12 15±15 11±11 31±25 15±13 13±09 12±13 7±8
Water 39±24 20±15 23±18 19±14 17±14 33±19 14±11 13±10 12±11 6±4
Periodontal pockets deeper than 4 mm were considered to be pathological and 
selected for PPD analysis. The results are presented in Table 6. At baseline, there 
were no intergroup differences. During the study, PPD decreased significantly in 
all three groups (p<0.05). Intergroup analysis revealed marked differences at one, 
four and six month follow-ups (p<0.05). Pairwise comparison disclosed significant 
divergence in favor of PHMG-P. No clear differences were detected by the end 
of the study (Table 6). The lack of intergroup differences at 12 months may be 
attributed to the infrequent chairside administration of the antiseptics and to the 
fact that in periodontal treatment adequate plaque control is a greater determinant 
of success than antimicrobial supplements.
Table 6. Pocket Probing Depths and reduction in periodontal pockets over 4 mm 
prior to and after treatment.
Treatment 
Group
PPD, mm (Mean±SD) PPD reduction, mm (Mean±SD)
baseline 1  
month
4  
months
6  
months
12  
months
1  
month
4  
months
6  
months
12  
months
Total (12 
months-
baseline)
PHMG-P 6.5±1.5 5.5±1.6 5.2±1.5 5.0±1.5 5.0±1.6 -1.1±1.3 -0.3±1 -0.1±1 0.02±0.9 -1.5±1.4
CHX 6.4±1.7 5.8±1.7 5.6±1.8 5.4±1.9 5.1±1.9 -0.7±1.2 -0.2±1.4 -0.3±1.1 -0.2±1.2 -1.4±1.7
Water 6.4±1.7 5.8±1.7 5.5±1.8 5.3±1.7 5.1±1.9 -0.6±1.2 -0.3±1.4 -0.2±1.3 -0.2±1.2 -1.3±1.5
A PPD value of 6 mm was chosen as the threshold for surgical treatment need. At 
baseline,	the	mean	PPD	value	of	deep	periodontal	pockets	(≥	6	mm)	did	not	differ	
between the groups (p>0.05). Significant intergroup differences in PPD, in favor 
of PHMG-P treatment, were detected at the one, four and six month follow-ups. 
However, by the end of the study, no differences were detected (Table 7). 
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In general, the mean PPD value was reduced by 1.3-1.5 mm. The average PPD 
decreased from 6.5 to 5.0 mm, which is consistent with the results of other stud-
ies (113-115). In some cases a decline in PPD from over 6 mm to 5 mm or less 
after conservative periodontal therapy eliminated the need for surgical treatment. 
In the PHMG-P group, PPD declined more rapidly, reaching its minimum by six 
months. Half a year later, PPD means in the CHX and water groups caught up 
with the values in the PHMG-P group.
Table 7. Average Pocket Probing Depth and reduction of periodontal pockets over 6 
mm prior to and after treatment.
Treatment 
Group
PPD, mm (Mean±SD) PPD reduction, mm (Mean±SD)
baseline 1  month
4  
months
6  
months
12 
months
1  
month
4  
months
6  
months
12  
months Total 
PHMG-P 7.2±1.2 6.0±1.5 5.8±1.4 5.5±1.5 5.5±1.6 -1.2±1.3 -0.2±1.1 -0.2±1.1 0.02±0.9 -1.8±1.5
CHX 7.6±1.4 6.6±1.6 6.3±1.9 6.0±2.0 5.8±2.1 -1.0±1.2 -0.3±1.2 -0.3±1.1 -0.2±1.3 -1.7±1.9
Water 7.5±1.3 6.6±1.7 6.1±1.9 6.0±1.7 5.8±1.9 -0.9±1.2 -0.5±1.5 -0.2±1.3 -0.2±1.3 -1.7±1.7
At baseline, neither the total nor the average number of deep periodontal pockets 
(≥	6	mm)	per	patient	differed	between	treatment	groups	(Table	8).	During	the	
study, the number of pockets decreased significantly within the groups. No inter-
group differences were observed at any follow-up examination. However, in the 
PHMG-P group, there was a pronounced tendency towards more rapid closure of 
deep periodontal pockets (p>0.05). By the end of the study, only patients in the 
antiseptic groups no longer required surgery. All deep periodontal pockets of two 
patients in the PHMG-P group and one patient in the CHX group healed below 
the threshold value for surgical intervention. Reduction in the depth of periodon-
tal pockets reduces the need for surgery. However, a single patient with only one 
residual deep pocket still will require surgery, albeit not extensive. In the present 
study, all deep periodontal pockets of three patients in the antiseptic groups healed 
to the extent that periodontal surgery was no longer indicated. However, the pau-
city of data and the low number of clinical cases restrain any definite conclusions 
to be drawn from these results. 
Table 8. Absolute and average number of deep (> 6 mm) periodontal pockets prior 
to and after treatment. 
Treatment 
Group
 Absolute number of deep periodontal 
pockets 
Average number of deep periodontal 
pockets 
baseline 1  
month
4 
months
6 
months
12 
months
baseline 1  
month
4 
months
6  
months
12 
months
PHMG-P 245 157 128 102 89 12.9±6.7 8.3±3.4 6.7±3.4 6.0±3.5 5.6±4.1
CHX 250 201 174 146 133 11.9±8.4 9.6±7.3 8.3±8.1 7.7±7.4 7.0±8.7
Water 243 206 179 169 152 12.8±11.0 10.8±9.4 9.4±8.0 9.4±8.2 8.4±8.2
32
4.8 Effect of PHMG-P irrigation on microflora and 
inflammatory markers in patients with periodontitis
With respect to both cytokine concentrations and the bacterial counts, there were no 
intergroup differences at any follow up (p>0.05). However, certain variations and 
distinctions in microbial composition and dynamics of biomarkers were recorded. 
Total protein concentration followed a similar pattern in all the groups (Fig. 11). 
At the two-week time-point it decreased from the baseline value, then gradually 
increased up to 4 months. In the PHMG-P group the concentration of total protein 
increased from the baseline level, but in the CHX and water groups it remained 
below the initial titer. The decline of total protein amount in the CHX group was 
considerable	(p≤0.05),	whereas	none	of	the	changes	observed	in	the	PHMG-P	and	
water groups during the study were significant (p>0.05). 
IL-1β production in PHMG-P and water groups exhibited a peak at the 2 week time-
point and then declined below the initial level in case of PHMG-P and exceeded 
it in the water group. However, the changes were significant only in the PHMG-P 
group	(p≤0.05)	(Fig	11).	In	the	CHX	group	the	cytokine	level	declined	constantly	
until the end of the first month and then increased slightly (p>0.05). 
IL-8 is a chemokine, a chemoattractant for neutrophils (116). The dynamics of IL-8 
concentration	coincided	with	that	of	IL-1β	in	the	corresponding	groups	(Fig	11).	The	
chemokine showed elevated values at the 2 week time-point in the PHMG-P and water 
groups, followed by a gradual decline by 4 months. In the CHX group there were neg-
ligible fluctuations in IL-8 production, which remained relatively constant. No differ-
ences in intragroup levels of IL-8 were recorded at any follow-up examination (p>0.05).
IL-10 regarded as an anti-inflammatory cytokine can be produced by many immune 
cells such as macrophages and regulatory T-cells. It affects dendritic cells, mac-
rophages and several T-cell subsets (117). As an anti-inflammatory cytokine IL-10 
downregulates the cellular immune response. It seems that production of IL-10 
was	synchronized	with	the	dynamics	of	the	pro-inflammatory	cytokines	(IL-1β,	
IL-8 and IL-17A) to balance the strength of the immune response (Fig 11). No 
intragroup differences in IL-10 concentration were observed over the course of the 
study (p>0.05). Initially, the mean IL-10 level in the CHX group was about 3 times 
higher than in the other groups, but tended to decline with time. In the PHMG-P 
and water groups IL-10 increased from baseline to the 2 week time-point and then 
gradually declined by the 4 month time-point in the water group.
IL-17A is produced by T helper 17 subset of the T cell population (118). The recep-
tor which binds IL-17A coordinates local tissue inflammation and up-regulates 
a wide range of pro-inflammatory cytokines and chemokines (119). The level of 
IL-17A decreased steadily in the CHX group and fluctuated significantly in the 
PHMG-P group and insignificantly in the water group (Fig 11). 
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On the average, P. gingivalis was detected in 70.2% of patients suffering from 
severe chronic periodontitis. In all treatment groups, the changes in concentration 
of P. gingivalis were similar throughout the study (Fig 12). It decreased gradually 
in the PHMG-P and CHX groups up to the one month time-point. In the water 
group the P. gingivalis titer dropped more sharply within the first fortnight. From 
1 month to 4 months the bacterial count resumed an upward trend, but did not 
exceed the initial baseline value. The changes were significant only within the 
PHMG-P	group	(p≤0.05).	
At baseline T. denticola was detected on the average in 68% of the patients. The 
concentration in the CHX group gradually decreased by 2-week and 1-month 
time-points, followed by a slight increase, yet it did not regain the baseline level. 
The	changes	were	statistically	significant	(p≤0.05)	(Fig	12).	In	patients	treated	
with PHMG-P, T. denticola concentration dynamics showed an irregular pattern, 
increasing by the 2-week time-point then decreasing in 1 month, followed by re-
growth exceeding the initial level by the 4- month checkpoint. In patients from 
the control group the concentration of T. denticola after short 2 weeks increase, 
it declined by 1 month. The changes in PHMG-P and water groups were not sig-
nificant (p>0.05). 
In all three groups amount of T. forsythia (detected in 94.2% of total samples) 
decreased within a month and increased thereafter. However, the initial level was 
not regained (Fig 12). The changes became significant in the group treated with 
CHX	(p≤0.05).	
F. nucleatum was detected in every patient included in the study. Mechanical 
debridement and irrigation with CHX or PHMG-P decreased its in concentration 
during the first month, but the initial level was almost regained by 4 months (Fig 
12). Mechanical treatment along with flushing of periodontal pockets with water 
reduced the bacterial concentration at the 2-week follow-up, but further treatment 
had a limited effect and the concentration of F. nucleatum increased to approxi-
mately the original level.
A. actinomycetemcomitans (detected in 55.3% of total samples) titer rose during 
the first fortnight. Then A. actinomycetemcomitans count increased further in the 
water group, but decreased in the groups treated with antiseptics (Fig 12). Thereafter 
the A. actinomycetemcomitans count decreased to below the baseline level in all 
three groups. The changes within treatment groups were not significant (p>0.05).
On the average P. intermedia was detected in 59.6% of the samples. The P. inter-
media counts differed initially between subjects, but the differences were not sta-
tistically significant (p>0.05) (Fig 12). During the study P. intermedia in treatment 
groups decreased insignificantly (p>0.05). Mechanical debridement combined with 
water irrigation of the pockets cut concentration of microorganisms by 2 weeks, 
but they recovered by 1 month and further treatment reduced the P. intermedia 
count to levels comparable to the test groups.
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Although in the CHX group pro-inflammatory cytokines were not upregulated 
after 2 weeks, the increase in MMP-8 level in this group was similar to that in the 
PHMG-P and water groups. A rise in MMP-8 concentration at the 2 week follow-
up after baseline treatment may be associated with mechanical injury of tissues 
during SRP and release of bacterial LPS. A further decrease in MMP-8 coincided 
with a reduction in PI and the ratios of P. gingivalis, T. forsythia and P. intermedia. 
In contrast to the 2 week follow-up, at the 1 month time-point, after the second 
treatment session, MMP-8 concentration did not increase. This may be accounted 
for by the effect of treatment and improved oral hygiene, a decrease in the number 
of microorganisms of the red and orange complexes and the LPS burden. 
The	dynamics	of	IL-1β	and	MMP-8	were	similar	in	the	PHMG-P	and	water	group,	
confirming previous findings that MMP-8 is controlled by the cytokine (120). The 
above-described in vitro study on the effects of CHX and PHMG-P on the secre-
tion of inflammatory mediators by human gingival fibroblasts showed that CHX 
was able to arrest the accumulation of the pro-inflammatory cytokines IL-6, 8 and 
MMP-1 (121). In the present study CHX treatment, in contrast to PHMG-P, did 
not	induce	an	upsurge	of	IL-1β,	IL-8	IL-17A	level	in	subjects,	suggesting	that	the	
cytokines are not the only factors regulating MMP-8 production.
At baseline the concentrations of IL-17A registered in subjects were diverse. The 
cytokine level was higher in the CHX group than in the other groups. Previous 
longitudinal studies have shown that biomarker levels could vary considerably, 
and that their response to therapy was not simple (122). 
As previously reported, biomarker levels can exhibit considerable variability. In 
the present study diverse concentrations of cytokines were registered and this was 
reflected as high SD values as well as variegated response to therapy (122). In 
periodontal pathogenesis cytokines function in a complex network of overlapping 
intermolecular interactions, hence pathogenesis of periodontal disease is likely to 
be a far more complex process than previously assumed (21). 
The decrease in P. gingivalis, T. forsythia and P. intermedia counts coincided with 
improvement of clinical parameters such as PI, BOP and PPD. 
The reduction of P. gingivalis occurred at 2 weeks, but this was not accompanied 
by inhibition of the cytokines in the PHMG-P and water groups. Persistence of 
higher cytokine levels may be due to mechanical trauma during debridement, and 
the presence of LPS in the dental plaque, enhancing the original inflammatory 
response. 
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Alterations in the number of P. gingivalis and T. forsythia followed a similar pat-
tern in all groups: growth inhibition up to 1 month (debridement every fortnight), 
and regrowth afterwards. Without active intervention the sites were re-populated 
by the bacteria. 
The contrast in behavior of A. actinomycetemcomitans with that of the other 
bacteria might be explained by the fact that as some bacteria decreased, leaving 
vacant niches, A. actinomycetemcomitans proliferated and occupied these niches, 
and was displaced again by re-growth of other bacteria as the proportion of perio-
pathogens was restored.
It was observed that F. nucleatum count was restored to a greater extent than that 
of other bacteria. F. nucleatum is an essential microbe allowing anaerobes to bind 
to the plaque and facilitating biofilm development (123). The three month interval 
between treatment sessions was long enough for bacteria to repopulate the pockets.
The microbial count of every studied periodontopathogen in subgingival biofilm 
varied considerably between patients. This phenomenon of subject-to-subject het-
erogeneity in subgingival microbial profiles has been reported previously (124). 
The treatment displayed similar inhibiting effect on the tested bacteria, without 
statistically significant differences between treatment groups (p>0.05). In the same 
time changes in T. forsythia, A. actinomycetemcomitans, and F. nucleatum counts 
were	significant	within	antiseptic	groups	(p≤0.05).	
All studied microorganisms presumably played different roles in the development 
of inflammation. P. gingivalis and T. forsythia evidently played a key part, as all 
subjects carried heavy loads of these pathogens. The impact of CHX and PHMG-P 
on these microorganisms was similar (p>0.05). F. nucleatum behaved like an ordi-
nary microbe: its amount fell during the treatment but regained approximately the 
original level afterwards. A decline in LPS concentration during treatment resulted 
in the arrest of inflammation and a decrease in pro-inflammatory cytokines, with 
eventual improvement of clinical parameters, specifically PPD, BOP, and PI (125). 
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5 CONCLUDING REMARKS
5.1 Summary of major findings 
PHMG-P displayed anti-bacterial activity against standard quality control strains, 
periopathogens and S. mutans, even after a 20-fold dilution.
Both PHMG-P and CHX displayed cytotoxic effects towards fibroblasts at con-
centrations lower than those used in clinical practice. PHMG-P exhibited higher 
toxicity within a shorter time frame than CHX. 
Low	doses	of	PHMG-P	and	CHX	reduced	IL-1β-induced	secretion	of	PGE2, IL-6, 
IL-8 and MMP-1 by gingival fibroblasts. 
PHMG-P has a potential role in treatment of periodontal diseases. The studies 
confirm both its antimicrobial activity and the ability to lower concentrations of 
pro-inflammatory mediators.
Irrigation of periodontal pockets with PHMG-P according to the study protocol 
significantly reduced PPD in the short-term. However, by the end of this one-year 
trial, antiseptic irrigation had no long-term benefit on mean pocket depth.
High variability of inflammatory biomarkers and bacterial counts was observed. 
Antiseptic treatment caused changes in the biomarker concentrations and bacterial 
counts. The response to periodontal treatment was attributed mainly to mechani-
cal debridement, while the contribution of adjunctive antiseptics, administered 
according to the protocol applied in these studies, was limited.
Overall conclusion:
Preclinical studies confirmed the antimicrobial and anti-inflammatory proper-
ties of PHMG-P. However, the subsequent one-year clinical trial disclosed that 
adjunctive irrigation with PHMG-P solution during scaling and root-planing had 
only a  limited additional benefit: the therapeutic effect was attributable primarily 
to mechanical debridement.   
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5.2 Future perspectives
Based on the results of the studies presented in this thesis, further research is 
planned into the pharmacodynamics of antiseptics in periodontal pockets.
The following specific research aspects will be explored:
1. What concentration of antiseptic is retained in the periodontal pocket upon 
its delivery?
2. How long is the bactericidal concentration of antiseptics maintained at the site 
of administration?
3. How often antiseptic application procedure should be repeated?
A “split mouth experimental design” will be used. A major advantage of this 
technique is that the risk of interpersonal variation is circumvented and different 
treatments can be applied under the same conditions. The dental arch is divided 
into two equal parts, left and right. Each part is treated with different antiseptics 
(PHMG-P and CHX). Periodontal pockets will be rinsed with one of the antisep-
tics. The pocket contents will be aspirated immediately after administration and 
then after 0.5, 1, 3 and 5 min. The concentrations of antiseptics in the aspirated 
samples will be evaluated by mass spectrometry.
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